

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	NA	NA	X	NA	X	NA	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

Medication	Comments
Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate)	N/A

**OVERRIDE(S)**

Prior Authorization of Benefits

**APPROVAL DURATION**

Approval Duration: 1 year

**APPROVAL CRITERIA**

Requests for Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) may be approved if the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual is antiretroviral treatment naïve.

**Note:** Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) has black box warnings for lactic acidosis/severe hepatomegaly with steatosis and post treatment acute exacerbation of hepatitis B. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues in combination with other antiretrovirals. Stribild is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy have not been established in individuals co-infected with HBV and HIV-1. Severe acute exacerbations of hepatitis B have been reported in individuals who have discontinued Emtriva (emtricitabine) or Viread (tenofovir disoproxil fumarate). Hepatic function should be monitored closely upon discontinuation of Stribild therapy in individuals co-infected with HIV-1 and HBV.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.